Skyrizi

(risankizumab)
0.83 ML risankizumab-rzaa 90.4 MG/ML Prefilled Syringe [Skyrizi]1 ML risankizumab-rzaa 150 MG/ML Auto-Injector [Skyrizi]
View 4 more
NO BLACK BOX WARNING

Dosage & administration

Recommended Dosage

Plaque Psoriasis and Psoriatic Arthritis:

Crohn’s Disease:


Most viewed Skyrizi resources

Billing and Coding Guide
Coverage Authorization Request - Rheumatology
Coverage Authorization Appeal - Rheumatology
Letter of Medical Necessity - Rheumatology
View more

drug label

Skyrizi prescribing information

Have more Skyrizi questions?

Submit MSL Request
Learn More

Need to report a Skyrizi issue?

ONLINE FORM
Report adverse event
Learn More

prior authorization

Skyrizi Prior authorization resources

NOT PROVIDED BY BRAND
Complete Letter of Medical Necessity

NOT PROVIDED BY BRAND
Complete Coverage Authorization request

NOT PROVIDED BY BRAND
Complete Coverage Authorization appeals
Coverage Authorization Request - Rheumatology
Coverage Authorization Appeal - Rheumatology
Letter of Medical Necessity - Rheumatology
Coverage Authorization Request - Dermatology
Coverage Authorization Appeal - Dermatology
Letter of Medical Necessity - Dermatology
Coverage Authorization Request - Gastroenterology
Learn More

Benefits investigation

Enrollment Form - Rheumatology & Dermatology
Enrollment Form - Gastroenterology
Learn More

Reimbursement help (FRM)

Receive Assistance from an FRM Regarding Reimbursement Information
Learn More

financial assistance

Skyrizi Financial assistance options

Co-pay savings program

commercial only
Enroll in patient savings program
Learn More

Bridge program

commercial only
Enroll in Bridge Program
Learn More

Foundation programs

under insured
no insurance
goverment insurance
65+
Abbvie Patient Assistance Program Application - English
Abbvie Patient Assistance Program Application - Spanish
Learn More

patient education

Skyrizi Patient education

Getting started on Skyrizi

Instructions For Use -Plaque Psoriais
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Instructions For Use - Psoriatic Arthritis
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Instructions For Use - Crohn's Disease
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

Patient toolkit

About Skyrizi - Plaque Psoriasis
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Before and After - Plaque Psoriais
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
About Skyrizi - Psoriatic Arthritis
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
About Skyrizi - Crohn's Disease
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Learn More

people also ask

Skyrizi FAQs

Is there a pregnancy exposure registry for SKYRIZI?Yes, there is a pregnancy exposure registry for SKYRIZI that monitors outcomes in women who become pregnant while treated with the medication. Patients can enroll by calling 1-877-302-2161 or visiting http://glowpregnancyregistry.com.
What is the risk of using SKYRIZI during pregnancy?Available data on risankizumab use in pregnant women are insufficient to establish a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes. However, monoclonal antibodies can be actively transported across the placenta, and SKYRIZI may cause immunosuppression in the in utero-exposed infant. Additionally, there are adverse pregnancy outcomes in women with inflammatory bowel disease.
What is the background risk of birth defects and miscarriage in the general population?In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.
Is SKYRIZI detected in human milk?There is no data on the presence of risankizumab in human milk. However, maternal IgG is known to be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for SKYRIZI and any potential adverse effects on the breastfed infant from the medication or from the underlying maternal condition.
Is SKYRIZI safe and effective in pediatric patients?The safety and efficacy of SKYRIZI in pediatric patients (less than 18 years of age) have not been established.
Is there a difference in safety and efficacy of SKYRIZI between older and younger subjects?Of the subjects with plaque psoriasis or psoriatic arthritis exposed to SKYRIZI, a total of 185 subjects were 65 years or older, and 13 subjects were 75 years or older. No overall differences in safety or effectiveness were observed between older and younger subjects who received SKYRIZI. However, the number of subjects aged 65 years and older was not sufficient to determine whether they respond differently from younger subjects.
FAQ Data Source

Can't find what you're looking for?

Our trained staff can help you:
Please note:
  • Access to a Field Reimbursement Manager (FRM) or Medical Science Liaison (MSL) varies by brand and may require talking with your rep first.
  • Samples are provided at the discretion of the brand.
  • We are unable to collect Protected Health Information (PHI), fill out forms, or submit them on your behalf.